In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March ...

Results showed that FGFR2 gene deletion led to significantly fewer precancerous lesions and delayed PDAC tumor formation ...

Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage ...

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Pancreatic cancer is projected to become the second-deadliest cancer by 2030. By the time it's diagnosed, it's often ...

The market regulator has once again extended the deadline for registered entities (REs) to adopt Cybersecurity and Cyber ...